Moffitt Presentation at ASH 2022

Location

Type

Title

Presenting Author

2:42-3:35 p.m.

New Orleans Theater AB

Scientific Workshop

What Did We Learn from Ccus Data Registry to Clinical Trial?

Zhuoer Xie, MD

Location

Type

Title

Presenting Author

10 a.m.

343-345

Oral

45: XPO1 Overexpression Is a Mechanism of Resistance to Eprenetapopt and 5-Azacitidine Therapy That Can be Therapeutically Exploited for the Treatment of TP53 Mutated Myeloid Malignancies

Traci L. Kruer, PhD

2 p.m.

La Nouvelle Orleans Ballroom AB

Oral

259: Association of Metabolic Tumor Volume (MTV) and Clinical Outcomes in Second-Line (2L) Relapsed/Refractory (R/R) Large B-Cell Lymphoma (LBCL) Following Axicabtagene Ciloleucel (Axi-Cel) Versus Standard-of-Care (SOC) Therapy in ZUMA-7

Frederick L. Locke, MD

3 p.m.

293-294

Oral

824: The Long Non-Coding RNA MALAT1 Is Necessary for Hematopoietic Stem and Progenitor Cell Expansion and Preleukemic Myeloproliferation in TET2 Deficient Myeloid Neoplasms

Nana Adjoa Ben-Crentsil

3:15 p.m.

R02-R05

Oral

252: Racial and Ethnic Differences in Clinical Outcomes Among Multiple Myeloma Patients Treated with CAR T Therapy

Lauren C. Peres, PhD, MPH

5 p.m.

Great Hall A/D

Oral

365: Phase I Trial of CD8-Depleted Human Leukocyte Antigen (HLA) Mismatched Unrelated Donor Lymphocyte Infusion (DLI) to Achieve Remissions in Myelodysplastic Syndrome (MDS) and Secondary Acute Myeloid Leukemia (sAML)

Hany Elmariah, MD, MS

5:30-7:30 p.m.

Hall D

Poster

2039: Baseline CRP and Ferritin Identify Patients at High Risk of Poor Outcomes after Axicabtagene Ciloleucel Despite Corticosteroid Prophylaxis

Rawan Faramand, MD

5:30-7:30 p.m.

Hall D

Poster

2043: Sarcopenia Prevalence and Influence on the Development of Toxicity and Length of Stay in Patients with Relapsed and Refractory Myeloma Treated with Commercial Anti-BCMA CART Cells

Ciara L. Freeman, MSc, FRCPath, MBBChir, MRCP

5:30-7:30 p.m.

Hall D

Poster

2268: Comparing Outcomes of Outpatient Vs. Inpatient High-Dose Melphalan Based Conditioning Regimens Followed By Autologous Hematopoietic Cell Transplantation in Myeloma

Taiga Nishihori, MD

5:30-7:30 p.m.

Hall D

Poster

2274: Real-World Patient-Reported Outcomes Among Recipients of Axicabtagene Ciloleucel for Relapsed/Refractory Large B Cell Lymphoma

Heather S. L. Jim, PhD

5:30-7:30 p.m.

Hall D

Poster

1467: Transcriptome Analysis and Machine Learning Prioritize Therapeutic Strategies for High-Risk Pediatric AML Patients of the KMT2A-Fusion Subgroup

Alyssa Obermayer

5:30-7:30 p.m.

Hall D

Poster

1484: Secondary AML Mutations Confer Poor Prognosis in Patients with ELN Favorable Risk NPM1-Mutated AML

Onyee Chan, MD

5:30-7:30 p.m.

Hall D

Poster

1491: The Prognostic Impact of FLT3 in NPM1-Mutated AML: Co-Occurrence of FLT3-ITD and FLT3-TKD Confers Poor Outcomes

Onyee Chan, MD

5:30-7:30 p.m.

Hall D

Poster

2118: Similar Benefits of High-Dose Melphalan Based Conditioning Regimens Followed By Autologous Hematopoietic Cell Transplantation in Elderly Myeloma Population Compared to the Younger Group: Single Center Experience

Taiga Nishihori, MD

5:30-7:30 p.m.

Hall D

Poster

1848: A Multiomic Approach to Reversing Therapy Resistance in Multiple Myeloma Using Paired Ex Vivo Drug Sensitivity Measures and RNA Sequencing Data

Praneeth Reddy Sudalagunta, PhD

5:30-7:30 p.m.

Hall D

Poster

2121: IPSS-Molecular but Not Individual Mutations Predicts Outcomes of Patients with Myelodysplastic Syndrome (MDS) after Allogeneic Hematopoietic Cell Transplantation (Allo-HCT): A Mayo Clinic Cohort

Razan Mohty, MD

5:30-7:30 p.m.

Hall D

Poster

2126: Conditioning Regimen Intensity and Donor Choice Do Not Impact Outcomes of Patients (pts) with Acute Myeloid Leukemia (AML) after Allogeneic Hematopoietic Cell Transplantation (Allo-HCT) in First Complete Remission (CR1): An EBMT Analysis

Razan Mohty, MD

5:30-7:30 p.m.

Hall D

Poster

1755: Characterization of TP53-Mutated Myelodysplastic Syndromes and Impact of Allelic Status and Concurrent Cytogenetic Abnormalities on Survival Outcomes

Luis E. Aguirre, MD

5:30-7:30 p.m.

Hall D

Poster

1757: Luspatercept for Treatment of Lower Risk Myelodysplastic Syndromes: Real World Data Replicates Medalist Study Results and Confirms Activity Among Hypomethylating Agents and Lenalidomide Treated Patients

Rami S. Komrokji

5:30-7:30 p.m.

Hall D

Poster

1306: Multiple Myeloma Evolution Is Characterized By Dynamic Epigenetic Landscapes

Rafael Renatino-Canevarolo, PhD

5:30-7:30 p.m.

Hall D

Poster

1662: The Role of Prophylactic Chemotherapy for the Prevention of Central Nervous System Relapse in Patients with Large B Cell Lymphoma: A Meta-Analysis

Jose Sandoval-Sus, MD

5:30-7:30 p.m.

Hall D

Poster

1752: Co-Existing ASXL1 and SF3B1 Mutations Carried Worse Outcome Than ASXL1 or SF3B1 Mutations Alone

Jinming Song, MD, PhD

5:30-7:30 p.m.

Hall D

Poster

1368: Updated Outcomes from the Historical Control Study SCHOLAR-3 Contextualizing ZUMA-3 Results of Brexucabtagene Autoleucel (KTE-X19) in Adult Patients with Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia (R/R B-ALL)

Bijal D. Shah, MD

Location

Type

Title

Presenting Author

9:30 a.m.

252-254

Oral

463: A Product of “Clash of Titans” or True Reflection of Disease Biology? Validation of 2022 WHO and ICC Classifications in a Large Dataset of Patients with Myelodysplastic Syndrome

Somedeb Ball, MD

10 a.m.

252-254

Oral

465: Validation of the Molecular International Prognostic Scoring System (IPSS-M) Risk Stratification Model for Myelodysplastic Syndromes

Luis E. Aguirre, MD

12:45 p.m.

271-273

Oral

538: Outcomes of Acute Myeloid Leukemia Relapsed Post-Allogeneic Hematopoietic Stem Cell Transplant Treated with Hypomethylating Agents and Venetoclax Combination: A Single Center Experience

Filip Ionescu, MD

4:30 p.m.

R06-R09

Oral

457: Efficacy and Safety of Ruxolitinib for Treatment of Symptomatic Chronic Myelomonocytic Leukemia (CMML): Results of a Multicenter Phase II Clinical Trial

Eric Padron, MD

5:15 p.m.

343-345

Oral

604: Post-Allogeneic Stem Cell Transplant Outcomes in Patients Treated with Hypomethylating Agent Plus Venetoclax Compared to CPX-351

Akriti G Jain, MD

6-8 p.m.

Hall D

Poster

3073: Assessment of the Molecular International Prognostic Scoring System (IPSS-M) Risk Stratification Model in Hypoplastic Myelodysplastic Syndromes

Luis E. Aguirre, MD

6-8 p.m.

Hall D

Poster

3076: Synergistic Activity of Luspatercept and Erythroid Stimulating Agents Combination for Treatment of Anemia in Lower-Risk Myelodysplastic Syndromes

Rami S. Komrokji, MD

6-8 p.m.

Hall D

Poster

3099: Hypoplastic MDS: Validation of the New World Health Organization 2022 Proposal

Zaker I. Schwabkey, MD

6-8 p.m.

Hall D

Poster

2923: Autologous Hematopoietic Cell Transplant Consolidation for First Response Is Associated with Longer Survival in Patients with Nodal Peripheral T-Cell Lymphoma

Yumeng Zhang, MD

6-8 p.m.

Hall D

Poster

2661: Acid Ceramidase (ASAH1) Is a Key Mediator of Drug Resistance in Refractory Multiple Myeloma

Ryan T Bishop, PhD

6-8 p.m.

Hall D

Poster

3251: Daratumumab Based Response Adapted Therapy for Older Adults with Newly Diagnosed Multiple Myeloma: Interim Analysis of Phase II Study

Rachid C. Baz, MD

6-8 p.m.

Hall D

Poster

3334: A Phase1/1b Dose Escalation/Dose Expansion Study of Prgn-3007 Ultracar-T Cells in Patients with Advanced Hematologic and Solid Tumor Malignancies

Javier Pinilla Ibarz, MD

6-8 p.m.

Hall D

Poster

3631: Discordance between Patient Goals and Treatment in Older AML Patients

Sara Marie Tinsley-Vance, PhD

6-8 p.m.

Hall D

Poster

3400: Sirolimus Results in Similar Outcomes to Tacrolimus for Gvhd Prophylaxis after Haploidentical Peripheral Blood Stem Cell Transplantation with Post-Transplant Cyclophosphamide

Hany Elmariah, MD, MS

6-8 p.m.

Hall D

Poster

3105: Targeting Inflammatory Pathways to Reverse Immunosuppressive Tumor Microenvironment in Chronic Lymphocytic Leukemia

Angimar Uriepero, M.D.

6-8 p.m.

Hall D

Poster

2698: The Impact of Chronic Kidney Disease on Hospitalization Outcomes in Patients Admitted with Acute Myeloid Leukemia: A Nationwide Analysis Using the National Inpatient Sample Database (2015-2019)

Mohammad Ammad Ud Din, MBBS

6-8 p.m.

Hall D

Poster

3039: Disease Progression and Leukemic Transformation in Patients With Lower-Risk Myelofibrosis (MF): An Analysis from MOST

Rami S. Komrokji

Location

Type

Title

Presenting Author

3:15 p.m.

243-245

Oral

855: Phase 1 Results of the First-in-Class CXCR1/2 Inhibitor SX-682 in Patients with Hypomethylating Agent Failure Myelodysplastic Syndromes

David A. Sallman, MD

5 p.m.

Hall E

Oral

981: Ameli-01: A Phase I Trial of UCART123v1.2, an Anti-CD123 Allogeneic CAR-T Cell Product, in Adult Patients with Relapsed or Refractory (R/R) CD123+ Acute Myeloid Leukemia (AML)

David A. Sallman, MD

6-8 p.m.

Hall D

Poster

4706: Outpatient Treatment with Anti-Sars-Cov-2 Monoclonal Antibodies and Remdesivir for COVID19 Infections Demonstrates Encouraging Outcomes in Hematopoietic Stem Cell Transplant Recipients: A Single-Center Experience

Rawan Faramand, MD

6-8 p.m.

Hall D

Poster

3345: Real-World Impact of Time from Leukapheresis to Infusion (Vein-to-Vein Time) in Patients with Relapsed or Refractory (r/r) Large B-Cell Lymphoma (LBCL) Treated with Axicabtagene Ciloleucel

Frederick L. Locke, MD

6-8 p.m.

Hall D

Poster

3346: Network Meta-Analysis (NMA) of Chimeric Antigen Receptor (CAR) T-Cell Therapy for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL) after 2 Prior Treatments Using Published Comparative Studies

Frederick L. Locke, MD

6-8 p.m.

Hall D

Poster

3355: Patterns of Relapse and Clinical Outcomes in Multiple Myeloma Patients after Anti-BCMA CAR T-Cell Therapy: Implications for Patient’s Monitoring after CAR T-Cell Therapy

Omar Alexis Castaneda Puglianini, MD

6-8 p.m.

Hall D

Poster

4406: Clone Size By Conventional Cytogenetics in Myelodysplastic Syndromes Correlates with Clinical Features and Outcomes

Rami S. Komrokji, MD

6-8 p.m.

Hall D

Poster

4410: Assessment of the Molecular International Prognostic Scoring System (IPSS-M) Risk Stratification Model in Therapy-Related Myelodysplastic Syndromes

Luis E. Aguirre, MD

6-8 p.m.

Hall D

Poster

 4770: Comparing Survival Outcomes of Autologous and Allogeneic Hematopoietic Cell Transplantation in Patients with Relapsed/Refractory Nodal Peripheral T-Cell Lymphoma

Yumeng Zhang, MD

6-8 p.m.

Hall D

Poster

4633: Phase 1/1b Safety Study of Prgn-3006 Ultracar-T in Patients with Relapsed or Refractory CD33-Positive Acute Myeloid Leukemia and Higher Risk Myelodysplastic Syndromes

David A. Sallman, MD

6-8 p.m.

Hall D

Poster

4903: Associations between Patient-Reported Outcomes and 90-Day Response to Chimeric Antigen Receptor T-Cell Therapy: A Bayesian Network Analysis

Laura B. Oswald, PhD

6-8 p.m.

Hall D

Poster

4716: Belumosudil Impacts Immunosuppression Pharmacokinetics in Patients with Chronic Graft-Versus-Host Disease

Rawan Faramand, MD

6-8 p.m.

Hall D

Poster

4566: A Phase I Study of Safety, Tolerability and Immunological Effects of SVN53-67/M57-KLH in Patients with Multiple Myeloma Receiving Lenalidomide Maintenance Therapy

Othman Salim Akhtar, MD

6-8 p.m.

Hall D

Poster

3666: Complications during Delivery Hospitalizations in Women with Thalassemia: An Analysis of the National Inpatient Sample Database (2002-2019)

Mohammad Ammad Ud Din, MBBS

6-8 p.m.

Hall D

Poster

4838: Evaluation of Representation of Women As Authors in Pivotal Trials Supporting US Food and Drug Administration Approval of Novel Hematological Drugs

Muhammad Zain Farooq, MD

6-8 p.m.

Hall D

Poster

4616: Bispecific CD33/CD123 Targeted Chimeric Antigen Receptor T Cells for the Treatment of Acute Myeloid Leukemia

Justin C. Boucher, PhD

6-8 p.m.

Hall D

Poster

4307: SHP2 Inhibition Suppresses RAS-ERK Signaling, the Development of JAK2 Inhibitor Persistence, and MPN Development in Pre-Clinical Models of Myeloproliferative Neoplasms

Garima Pandey